Published in final edited form as:

J Cell Biochem. 2014 May ; 115(5): 805–811. doi:10.1002/jcb.24745.

Standardizing Analysis of Circulating MicroRNA: Clinical and Biological Relevance

Nicholas H. Farina^{1,2}, Marie E. Wood^{1,3}, Scott D. Perrapato^{1,4}, Christopher S. Francklyn^{1,2}, Gary S. Stein^{1,2}, Janet L. Stein^{1,2}, and Jane B. Lian^{1,2,*}

¹Vermont Cancer Center for Basic and Translational Research, University of Vermont College of Medicine, Burlington, Vermont 05405

²Department of Biochemistry, University of Vermont College of Medicine, Burlington, Vermont 05405

³Division of Hematology/Oncology, Department of Medicine, University of Vermont College of Medicine, Burlington, Vermont 05405

⁴Division of Urology, Department of Surgery, University of Vermont, College of Medicine, Burlington, Vermont 05405

Abstract

Circulating microRNAs (c-miRNAs) provide a new dimension as clinical biomarkers for disease diagnosis, progression, and response to treatment. However, the discovery of individual miRNAs from biofluids that reliably reflect disease states is in its infancy. The highly variable nature of published studies exemplifies a need to standardize the analysis of miRNA in circulation. Here, we show that differential sample handling of serum leads to inconsistent and incomparable results. We present a standardized method of RNA isolation from serum that eliminates multiple freeze/thaw cycles, provides at least 3 normalization mechanisms, and can be utilized in studies that compare both archived and prospectively collected samples. It is anticipated that serum processed as described here can be profiled, either globally or on a gene by gene basis, for c-miRNAs and other non-coding RNA in the circulation to reveal novel, clinically relevant epigenetic signatures for a wide range of diseases.

Keywords

circulating microRNA; c-miRNA; miRNA; serum; plasma; qPCR; RNA isolation; biomarker; clinical sample

Background

The discovery of microRNAs (miRNAs) in the circulation of human patients (Mitchell, 2008), (Chen, 2008) spawned a plethora of studies with a goal to identify novel miRNA

*Corresponding Author: Jane B. Lian, Department of Biochemistry, University of Vermont, E210B Given Building, 89 Beaumont Avenue, Burlington, VT 05405, Phone: (802) 656-4872, Fax number: (802) 656-8216, Jane.Lian@med.uvm.edu.

Competing Interests

The authors declare no conflicts of interest.

biomarkers of disease progression in a wide variety of maladies including cancers, heart disease, and diabetes. There is compelling evidence that circulating miRNAs (c-miRNAs) can be used as effective clinical biomarkers of disease diagnosis, prognosis, and success of treatment (Grasedieck, 2013), (Williams, 2013). However, when c-miRNA profiles obtained by different laboratories are directly compared for the same disease, there is minimal consistency in miRNA expression (Leidner, 2013), (Sapre, 2013). This conundrum poses a question that must be resolved for application of c-miRNAs as clinically relevant disease biomarkers: How can c-miRNAs be reproducibly isolated, detected, and analyzed from both archival (banked) and prospectively collected samples?

C-miRNAs are small (18–24 nt) non-coding RNA molecules that are secreted by cells in membrane encapsulated particles that include exosomes (Valadi, 2007) or microvesicles (Skog, 2008), bound to proteins (Wang, 2010), and can be free, not bound to any biomolecule (Wang, 2010). Once secreted, c-miRNAs function as signaling molecules that exchange epigenetic information between cells (Valadi, 2007), (Skog, 2008). It is hypothesized that the packaging of an individual c-miRNA, being membrane encapsulated, protein-bound, or unbound, determines the cell(s) targeted for specific signals. Additionally, c-miRNAs represent epigenetic changes that can reflect early cellular modifications prior to disease detection, using currently available diagnostic methods, and to changes in cellular activity corresponding to disease progression (Valadi, 2007), (Chen, 2008), (Mitchell, 2008), (Skog, 2008).

As a clinical biomarker, c-miRNAs appear to be stable as their expression can be detected in archival patient plasma and serum samples stored long-term at -80°C as well as after treatment with RNases (Turchinovich, 2011), (Bryant, 2012), (Köberle, 2013). Interestingly, while c-miRNAs in plasma are reportedly detected after up to 8 freeze/thaw cycles without significant changes in expression levels (Mitchell, 2008), it is becoming increasingly evident that the stability of c-miRNAs in serum may not be as robust (Köberle, 2013). However, serum is the preferred circulating fraction for c-miRNA detection as plasma contains cellular material that may introduce contaminating cellular miRNAs from apoptotic or lysed cells (e.g. RBCs, platelets) as well as anti-coagulants such as heparin that can inhibit downstream methodologies (Hastings, 2012), (Kim, 2012). Thus, there is a critical need to develop a protocol for c-miRNA isolation from serum that reduces sample degradation without introducing factors inhibitory to downstream assays. Figure 1 illustrates the initial species of c-miRNA in serum (Figure 1A) and potential outcomes of c-miRNAs in serum that is handled and processed inconsistently, resulting in differential and incomparable expression levels (Figure 1B).

Standardization of operating procedures for biomedical research is imperative. The Early Detection Research Network (ERDN) has developed a Standard Operating Procedure for the collection of serum and plasma with guidelines as to the time and temperature for sample processing (Tuck, 2009). Here, we provide an additional standardized method of downstream serum handling for RNA isolation (based on (Li, 2012)) that will allow for direct comparison of c-miRNAs in archived patient serum with prospectively collected serum. Our protocol rectifies several known issues with detecting c-miRNAs in serum by reducing freeze/thaw cycles, maintaining precise volumes through uniform RNA isolation,

and adding a synthetic RNA as a normalization control (as illustrated in Figure 2). We anticipate that RNA obtained with this method can be readily used for global miRNA profiling studies, next generation sequencing, or qPCR of individual miRNAs.

Results

The materials and methods section provides the detailed protocol as outlined in Figure 2. In this results section, we provide evidence that justifies our proposed recommendations for critical procedures in the analysis of c-miRNAs from clinical serum samples.

Normalization Requirements for Circulating miRNAs

Unlike cellular RNA that can be directly compared to endogenous housekeeping genes such as U6 and GAPDH, there are no established cell-free RNAs in circulation to which levels of c-miRNAs can be normalized. Many groups have assessed the levels of potential reference genes between diseased and healthy patients (Sanders, 2012), (Zhu, 2012), (Song, 2012), (Wang, 2013), (Chen, 2013). However, these proposed normalization factors are disease specific and cannot be universally used. Moreover, normalization methods that eliminate the need for endogenous controls, such as Global Means or Quantile normalization, are only suitable for large datasets. Thus, to allow for sample-to-sample comparisons, precise volumes are used at each step of the RNA isolation (Figure 2 and Table 1). Furthermore, 1.6×10^8 copies of a synthetic miRNA mimic that is only expressed in *C. elegans* and not in mammals is spiked-in to each serum sample prior to RNA isolation as recommended by the manufacturer. This technique allows for 3 concurrent normalization methods: relative miRNA level per serum volume; relative miRNA level as compared to spiked-in control; absolute miRNA copy number per serum volume.

RNA Isolation: Stringent Control of Parameters to Reduce Sample Variability

Levels of c-miRNA isolated using different methods should not be directly compared as the recovery of c-miRNA varies dramatically (Li, 2012), (Page, 2013). Thus, we tested two frequently utilized commercially available miRNA isolation kits: Ambion® *mirVana*™ PARIS™ and miRNeasy Serum/Plasma kit. The general methodology for both is similar, where RNA from serum is isolated by an organic extraction with phenol/chloroform followed by salt and ethanol washes on a silica membrane. As previously described, the volumes are kept consistent (Table 1) and a synthetic control is spiked-into the serum prior to RNA isolation (Figure 2). The recovery of spiked-in control RNA between the two kits is within 0.5 Ct of each other indicating similar RNA isolation efficiency (Figure 3). In agreement with prior work (Li, 2012), all 3 miRNAs assayed for, miR-451a, miR-223-3p, and miR-23a-3p, are detected at levels more than 8 fold higher in RNA isolated using the miRNeasy Serum/Plasma kit as compared to the Ambion® *mirVana*™ PARIS™ kit (Figure 3). We anticipate that low abundance miRNAs can be more readily detected in RNA isolated with the miRNeasy Serum/Plasma kit. The ability to detect low abundance miRNAs may allow for the identification of c-miRNA biomarkers of early stage disease.

To further reduce sample-to-sample variability and increase reproducibility of c-miRNA detection, we automated all steps following the organic extraction on a QIAcube. Briefly,

600 μ L of the aqueous phase, containing c-miRNAs, along with filter columns, ethanol, buffer RWT, buffer RPE, and RNase-free water are loaded into a QIAcube. All subsequent RNA isolation steps, including ethanol precipitation, membrane binding, and salt washes, are performed and RNA recovered. While this protocol describes the use of a QIAcube (QIAGEN), we expect similar robotics to greatly improve sample consistency. We compared c-miRNA expression between individual animals and between pooled serum from male or female animals. The levels of detected c-miRNAs are consistent between groups, and varied based on genotype and sex indicating that automation reduced sample variability and may allow for the detection of subtle differences in c-miRNA levels (Figure 4).

Repeated Freeze/Thaw Cycles Cause Inconsistent C-miRNA Detection

Clinical studies designed to identify c-miRNAs as biomarkers will likely compare retrospective archived serum with prospectively collected samples. Consequently, a standard operating procedure must account for the procurement and handling of such samples in a uniform manner. In accordance with the EDRN SOP (Tuck, 2009), archived serum is stored at -80°C , requiring at least one freeze/thaw cycle prior to c-miRNA detection. We collected serum from 6 healthy human patients and stored it at least overnight at -80°C to mimic archived sample conditions. After an initial thaw on ice, each serum sample was divided into 250 μ L aliquots. The RNA was immediately isolated from one aliquot (first thaw), as previously described, while the remaining aliquots were stored at -80°C at least overnight. Of the remaining aliquots, one was thawed slowly on ice while one was thawed rapidly at 37°C to assess the effects of differential sample handling on c-miRNA levels.

In agreement with the reduced stability of c-miRNAs in serum as compared to plasma (Köberle, 2013), (Leidner, 2013), both the level and pattern of c-miRNAs change with subsequent freeze/thaw cycles (Figure 5). Interestingly, the levels of each c-miRNA are not affected in a similar manner, suggesting that stability may be related to the cell-free fraction of the individual c-miRNA, being membrane encapsulated, protein-bound, or unbound. Surprisingly, two c-miRNAs, miR-93-5p and miR-451a, are detected at significantly higher levels when the serum is thawed rapidly at 37°C . One explanation is that these miRNAs are contained within large particles that sediment in the initial centrifugation step to remove cryoprecipitates when serum is thawed at 4°C that are disrupted or lysed at 37°C , releasing c-miRNAs. Together, our data indicate that inconsistent sample preparation and handling dramatically alters the profile of circulating miRNA in serum leading to irreproducible results.

Method Validation

To validate our method, we examined the expression of c-miRNAs in serum collected from men with a positive diagnosis of prostate cancer. Serum from these men was stored at -80°C for various lengths of time (from days to months), modeling a direct comparison of archival with prospectively collected samples, and RNA was isolated accordingly. The expression of two miRNAs with elevated levels in solid tumors of many cancers including prostate cancer, miR-21-5p (Baer, 2013), (Mishra, 2013) and miR-93-5p (Hamilton, 2013) was determined. In agreement with these studies, both miR-21-5p (Figure 6A) and miR-93-5p (Figure 6B) are detected at significantly higher levels in men diagnosed with prostate cancer as

compared to cancer-free individuals. Thus, when clinical serum samples are analyzed in a consistent manner as outlined here, c-miRNAs that are deregulated in disease states may prove to be effective novel biomarkers in patients at risk for or with early stage disease and can be monitored during disease progression and treatment to assess response to therapies.

Discussion

Consistent and reproducible isolation and detection of miRNAs in circulation of patients currently poses a major problem for the biomedical community. Institutions around the world have extensive tissue and serum banks that provide an existing repository of retrospective samples in which Investigators can identify c-miRNAs as novel disease biomarkers. Moreover, the desire to monitor disease progression and response to treatment necessitates longitudinal studies. Given the clinical need to compare retrospective and prospective samples collected at different times, blood fractions must be stored and processed in a manner that will yield highly confident results. Our results add to the growing body of evidence that improper sample handling likely leads to differential c-miRNA stability and hence, highly variable results. Here, we present a standardized method for isolating miRNAs in circulation from archived and freshly collected serum to reduce technical variability between protocols.

Another problem facing investigators in the design of retrospective studies is how to carefully handle precious, and often irreplaceable, patient samples. Many archived samples are stored in volumes larger than required for a single RNA isolation. Furthermore, future detection of other biomolecules, such as DNA and protein, may be desired from the same sample. Thus, we recommend dividing each serum sample into 1 mL aliquots and re-freezing unused aliquots to -80°C at time of RNA isolation. Proceeding with RNA isolation from at least 1 mL of serum followed by storage of RNA in small aliquots at -80°C for future analysis, eliminates multiple freeze/thaw cycles and precious patient samples are optimally utilized. Importantly for prospective studies, freshly isolated serum should be stored at -80°C at least overnight to allow for direct comparison to archival samples. It is anticipated that RNA isolated using this method is suitable for downstream detection of c-miRNAs using global platforms, such as SYBR and TaqMan-based qPCR profiling, hybridization-based microarrays, and deep sequencing, which offer the most comprehensive picture of c-miRNA levels. Here, we show consistent qPCR detection of individual c-miRNAs from serum. While not directly assessed, other circulating non-coding RNAs likely can also be reproducibly detected and profiled with high efficacy from RNA isolated as described.

Concluding Remarks

There are many clinical applications and basic experimental questions for which reproducible detection of circulating RNA from human patients can be used. Longitudinal studies that track patients over years, either prior to disease diagnosis or following treatment, may identify c-miRNAs as novel early detection biomarkers, those that can trace response to treatment, or a signature consisting of multiple c-miRNAs that is predictive of disease recurrence. Additionally, deregulated c-miRNAs in diseases provide exciting targets for

therapeutics development. Lastly, it will be interesting to investigate the relationship between c-miRNAs and the expression levels of the proteins encoded by the mRNAs that they target both in circulation and in diseased cells. Such knowledge can better guide treatment strategies using currently available drugs against these proteins and help design future therapeutics.

Materials & Methods

Human patient samples

Human samples were collected from healthy patient volunteers or from men diagnosed with prostate cancer. Blood and serum were collected by a trained professional at Fletcher Allen Health Care following written informed consent to an institutionally approved protocol (CHRS 04-004 and CHRS M13-042). All samples were de-identified and handled in accordance with HIPAA regulations.

Mouse samples

Animals were housed in an animal facility at The University of Vermont and cared for by a dedicated animal technician as per IUCAC approved protocol (#12-051). All mice used were in the C57Bl/6 background and approximately 10 months of age.

Serum Collection

Blood was collected from mice via cardiac puncture following an approved IUCAC protocol. Briefly, animals were sacrificed with CO₂, 0.8–1 mL of blood was collected from the beating heart using a 25 5/8 gauge needle, and blood allowed to clot at room temperature 30–60 minutes. Following centrifugation for 5 minutes at 2040*g in a bench-top centrifuge, the top translucent yellow phase was carefully removed and serum stored at –80°C until processed for RNA isolation. Blood was collected from human patients according to an institutionally approved protocol. Briefly, 10mL of blood was collected in 4 vials, allowed to clot for 10 minutes at room temperature, and centrifuged for 15 minutes at 2000 RPM in a clinical centrifuge. Serum was carefully removed from each vial, pooled, divided into 1mL aliquots, and stored at –80°C at least overnight until processed for RNA isolation to mimic conditions of archived patient samples.

Sample handling

Serum samples were thawed on ice over 1–2 hours and divided into 250 µL aliquots. For those serum samples undergoing multiple freeze/thaw cycles, aliquots were immediately re-frozen and stored at –80°C at least overnight. For the slow second thaw, samples were thawed on ice over 1–2 hours. For the fast second thaw, samples were thawed in a 37°C water bath for 30–60 seconds until just melted and immediately transferred to ice. Once thawed, 250 µL of serum was centrifuged 10 minutes at 16000*g at 4°C to remove cryoprecipitates. Exactly 200 µL of serum was removed and used for RNA isolation.

RNA isolation

We tested miRNA recovery of the *mirVana*[™] PARIS[™] (Ambion[®]-Life Technologies) or miRNeasy Serum/Plasma (QIAGEN) kits following manufacturers protocols. RNA was isolated from precisely 200 μ L of serum, 1.6×10^8 copies of synthetic ce-miR-39 mimic was spiked-in to each sample prior to addition of chloroform, and preset volumes were used when removing sample containing RNA as described (Table 1). The *mirVana* PARIS protocol was modified to include a second organic extraction and use of the smaller filter cartridges from the RNeasy-Micro Kit (Ambion[®]-Life Technologies). The miRNeasy protocol was modified for automation using a QIAcube (QIAGEN) for on-column washes and elution. The minimum recommended elution volume (Table 1) for each kit was used to produce the most concentrated RNA.

cDNA synthesis and quantitative RT-PCR

cDNA was synthesized using the miScript II RT kit (QIAGEN) according to the manufacturers instructions with the following modifications for a 10 μ L reaction. 5 μ L of total serum RNA was incubated with 2 μ L 5x HiSpec Buffer, 1 μ L Nucleics Mix, 1 μ L RNase-Free Water, and 1 μ L RT mix at 37°C 1 hour followed by enzyme deactivation for 5 minutes at 95°C. The cDNA was diluted 1:10 in RNase-Free water and miRNA detected using the miScript SYBR[®] Green PCR kit (QIAGEN). 10 μ L reactions were run in 384-well plates on an ABI ViiA7 (Applied Biosystems-Life Technologies). Spiked-in ce-miR-39 was detected with the Ce_miR-39_1 miScript Primer Assay (QIAGEN). Specific forward primers (Invitrogen-Life Technologies) for each miRNA were designed as the miRNA sequence and are identical for mouse and human: miR-21-5p 5' - TAGCTTATCAGACTGATGTTGA-3'; miR-23a-3p 5' - ATCACATTGCCAGGGATTTCC-3'; miR-93-5p 5' - CAAAGTGCTGTTCGTGCAGGTAG-3'; miR-223-5p 5' - TGTCAGTTTGTCAAATACCCCA-3'; miR-451a 5' - AAACCGTTACCATTACTGAGTT-3'.

Acknowledgments

Contract grant sponsor: NIH/NIDCR; Contract grant number: R37 DE012528-27

Contract grant sponsor: NIH/NCI; Contract grant number: P01 CA082834

Contract grant sponsor: NIH/NIAMS; Contract grant number: P01 AR48818

Contract grant sponsor: VCC/LCCRO Pilot Award

The authors would like to thank Morgan Czaja for serum collected from all mice, and Jennifer Holmes, Tiffany Rounds, and Art Weiss for procurement and de-identification of human serum samples. This publication was made possible by a Vermont Cancer Center Pilot Award from the Lake Champlain Cancer Research Organization to JBL, and by NIH Grant Numbers R37 DE012528-27 from the National Institute of Dental and Craniofacial Research to JBL, 1 P01 CA082834 from the National Cancer Institute to GSS, 5 P01 AR48818 from the National Institute of Arthritis and Musculoskeletal and Skin Disease to GSS, 5 P30 RR032135 from the COBRE Program of the National Center for Research Resources, and 8 P30 GM 103498 from the National Institute of General Medical Sciences.

References

- Mitchell PS, et al. Circulating microRNAs as stable blood-based markers for cancer detection. *Proc Natl Acad Sci U S A*. 2008; 105:10513–10518. [PubMed: 18663219]
- Chen X, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. *Cell Res*. 2008; 18:997–1006. [PubMed: 18766170]
- Grasedieck S, et al. Circulating microRNAs in hematological diseases: principles, challenges, and perspectives. *Blood*. 2013; 121:4977–4984. [PubMed: 23550041]
- Williams Z, et al. Comprehensive profiling of circulating microRNA via small RNA sequencing of cDNA libraries reveals biomarker potential and limitations. *Proc Natl Acad Sci U S A*. 2013; 110:4255–4260. [PubMed: 23440203]
- Leidner RS, et al. Dampening enthusiasm for circulating microRNA in breast cancer. *PLoS One*. 2013; 8:e57841. [PubMed: 23472110]
- Sapre N, Selth LA. Circulating MicroRNAs as Biomarkers of Prostate Cancer: The State of Play. *Prostate Cancer*. 2013; 2013:539680. [PubMed: 23577261]
- Valadi H, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol*. 2007; 9:654–659. [PubMed: 17486113]
- Skog J, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. *Nat Cell Biol*. 2008; 10:1470–1476. [PubMed: 19011622]
- Wang K, et al. Export of microRNAs and microRNA-protective protein by mammalian cells. *Nucleic Acids Res*. 2010; 38:7248–7259. [PubMed: 20615901]
- Turchinovich A, et al. Characterization of extracellular circulating microRNA. *Nucleic Acids Res*. 2011; 39:7223–7233. [PubMed: 21609964]
- Bryant RJ, et al. Changes in circulating microRNA levels associated with prostate cancer. *Br J Cancer*. 2012; 106:768–774. [PubMed: 22240788]
- Köberle V, et al. Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers. *PLoS One*. 2013; 8:e75184. [PubMed: 24073250]
- Hastings ML, et al. Sensitive PCR-based quantitation of cell-free circulating microRNAs. *Methods*. 2012; 58:144–150. [PubMed: 22884953]
- Kim DJ, et al. Plasma components affect accuracy of circulating cancer-related microRNA quantitation. *J Mol Diagn*. 2012; 14:71–80. [PubMed: 22154918]
- Tuck MK, et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. *J Proteome Res*. 2009; 8:113–117. [PubMed: 19072545]
- Li Y, Kowdley KV. Method for microRNA isolation from clinical serum samples. *Anal Biochem*. 2012; 431:69–75. [PubMed: 22982505]
- Sanders I, et al. Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. *Int J Urol*. 2012; 19:1017–1025. [PubMed: 22788411]
- Zhu HT, et al. Identification of suitable reference genes for qRT-PCR analysis of circulating microRNAs in hepatitis B virus-infected patients. *Mol Biotechnol*. 2012; 50:49–56. [PubMed: 21567136]
- Song J, et al. Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. *Dig Dis Sci*. 2012; 57:897–904. [PubMed: 22198701]
- Wang Y, et al. Identification of endogenous reference genes for RT-qPCR analysis of plasma microRNAs levels in rats with acetaminophen-induced hepatotoxicity. *J Appl Toxicol*. 2013 Apr 4. Epub ahead of print.
- Chen Q, et al. Identification and characterization of microRNAs controlled by the osteoblast-specific transcription factor Osterix. *PLoS One*. 2013; 8:e58104. [PubMed: 23472141]
- Page K, et al. Influence of plasma processing on recovery and analysis of circulating nucleic acids. *PLoS One*. 2013; 8:e77963. [PubMed: 24205045]
- Baer C, et al. Genome-wide epigenetic regulation of miRNAs in cancer. *Cancer Res*. 2013; 73:473–477. [PubMed: 23316035]

- Mishra S, et al. Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. *Oncogene*. 2013 Sep 16. Epub ahead of print.
- Hamilton MP, et al. Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif. *Nat Commun*. 2013; 4:2730. [PubMed: 24220575]

Figure 1. Potential fates of serum miRNAs based on sample handling

Multiple species of miRNAs and miRNA associated particles circulate and can be isolated from serum including free, unbound miRNAs, miRNAs bound to proteins, or membrane encapsulated miRNAs including those in microvesicles and exosomes (**A**). However, the miRNA complement in serum present after subsequent freeze/thaw cycles likely differs based on the conditions of the subsequent thaws (**B**). I, II, and III represent potential outcomes of non-standardized sample handling showing differential c-miRNA stability.

Figure 2. Sample handling and miRNA isolation schematic

This method is described in detail in the text. Briefly, all serum samples, whether archival or fresh, are stored at -80°C . Serum is slowly thawed on ice and 1 mL divided into 4 aliquots for RNA isolation. Centrifugation removes cryoprecipitates and exactly 200 µL serum/aliquot is used for RNA isolation using the miRNeasy Serum/Plasma kit (QIAGEN) with QIAcube (QIAGEN) automation. Following elution, RNA is pooled, divided into aliquots, and frozen for future use.

Figure 3. Serum miRNA isolation efficiency: *mirVana*TM PARISTM vs. miRNeasy Serum/Plasma

RNA was isolated from the same test mouse serum using the *mirVana*TM PARISTM (A) and miRNeasy Serum/Plasma (B) kits. The recovery of spiked-in control cel-miR-39 is similar between kits. However, all 3 tested miRNAs, miR-451a, miR-223-3p, and miR-23a-3p are detected at lower Ct values indicating higher expression in RNA isolated using the miRNeasy Serum/Plasma kit (compare B to A). Graphs show qRT-PCR miRNA detection, cycle threshold (Ct), and are of 3 technical replicates.

Figure 4. RNA isolation reproducibility using automation on a QIAcube

RNA was isolated from either individual animals (black bars) or pooled animals (gray and white bars). Levels of miR-23a-3p are consistent between comparable samples (black, gray, or white bars). Individual animals are litter-mates. Pooled serum is from litter-mate animals. Relative miRNA abundance is normalized to levels of spiked-in cel-miR-39.

Figure 5. Multiple freeze/thaw cycles introduce a high degree of variability in c-miRNA detection

The serum levels of 4 miRNAs, miR-21-5p (A, B), miR-23a-3p (C, D), miR-93-5p (E, F), and miR-451a (G, H) were determined in 6 healthy human patients. C-miRNA levels varied dramatically when RNA was isolated after 2 freeze/thaw cycles as compared to RNA isolated after the first thaw. The speed and temperature at which serum was thawed differentially affected miRNA levels (compare slow (4°C) thaw A, C, E, G to fast (37°C) thaw B, D, F, H). No RNA was recovered from sample 006 when thawed for a second time at 4°C. Relative miRNA abundance is normalized to levels of spiked-in cel-miR-39.

Figure 6. Method validation: miRNAs associated with prostate cancer are detected at increased levels in diseased human serum
 The expression miR-21-5p (A) and miR-93-5p (B) were determined in the serum from 10 men diagnosed with prostate cancer (cancer diagnosis). Both miR-21-5p (A) and miR-93-5p (B) are detected at elevated levels as compared to cancer-free controls. Relative miRNA abundance is normalized to levels of spiked-in cel-miR-39. Error bars are $\pm$ SEM, * $p < 0.01$, ** $p < 0.001$.

Table 1
Volumes used during RNA isolation

Consistent volume is critically important to sample reproducibility and comparison as there are no established normalizing factors.

<i>mirVana™ PARIS™ kit</i>		<i>miRNeasy Serum/Plasma kit</i>	
<u>Reagent/Sample</u>	<u>Volume</u>	<u>Reagent/Sample</u>	<u>Volume</u>
2x Denature Solution	200 µL	QIAzol	1 mL
Acid-Phenol:Chloroform 1	400 µL	Chloroform	200 µL
Aqueous Phase 1	350 µL	Aqueous Phase	600 µL
Acid-Phenol:Chloroform 2	350 µL	100% EtOH	900 µL
Aqueous Phase 2	275 µL	RNase-free water (eluate)	14 µL
100% EtOH	400 µL		
Elution Buffer	10 µL		